Donafenib Plus Sintilimab for Advanced HCC
Donafenib Combined with Sintilimab for Advanced HCC: a Single-arm, Single-center, Prospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase II study to evaluate the efficacy and safety of donafenib combined with sintilimab in patients with advanced HCC.
30 subjects with advanced HCC (Barcelona-Clinic- Liver-Cancer [BCLC] stage C, or China liver cancer staging [CNLC] IIIa/IIIb) will be enrolled in the study.
Part 1 (Safety Run-in): 6 patients will receive donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-day cycle.
Part 2: patients will receive donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.
Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510260
- The Second Affiliated Hospital of Guangzhou Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Advanced HCC (BCLC stage C or CNLC IIIa/IIIb ) with diagnosis confirmed by histology/cytology or clinically
- Patients who have Tumor recurrence after surgical resection or ablation are allowed to be included
- Patients who previously received local treatment, such as transcatheter arterial chemoembolization, transcatheter arterial embolization and radiotherapy, are allowed to be included
- At least one measurable lesion
- Child-Pugh score ≤7
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and hematologic function
- Life expectancy of at least 3 months
Exclusion Criteria:
- Diffuse HCC
- Macrovascular invasion involving the main trunk or inferior vena cava
- Central nervous system metastasis
- History of malignancy other than HCC
- Esophageal and/or gastric varices bleeding within 3 months prior to initiation of study treatment
- Uncontrolled ascites
- History of hepatic encephalopathy
- Patients who received prior systemic therapy (chemotherapy, targeted therapy or immunotherapy) or hepatic arterial infusion chemotherapy (HAIC) for HCC
- History of organ and cell transplantation
- Active severe infection; use of antibiotics within 2 weeks prior to injection of sintilimab
- Autoimmune disease or immune deficiency
- Severe organ (heart, kidney) dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Donafenib+sintilimab
Donafenib combined with sitilimab.
|
Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle. Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W. Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression free survival (PFS) assessed by investigators according to modified Response Evalutaion Criteria in Solid Tumors (mRECIST).
Time Frame: 18 months
|
The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events (AEs)
Time Frame: 18 months
|
Number of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), AE of special interest (AESI), serious adverse event (SAE), assessed by NCI CTCAE v5.0.
|
18 months
|
|
PFS assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1
Time Frame: 18 months
|
The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.
|
18 months
|
|
Objective response rate (ORR) assessed by investigators according to mRECIST.
Time Frame: 18 months
|
The percentage of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR).
|
18 months
|
|
Disease control rate (DCR) assessed by investigators according to mRECIST.
Time Frame: 18 months
|
The percentage of patients who had a tumor response rating of CR, PR, or stable disease (SD).
|
18 months
|
|
ORR assessed by investigators according to RECIST 1.1.
Time Frame: 18 months
|
The percentage of patients who had a best overall tumor response rating of CR or PR.
|
18 months
|
|
DCR assessed by investigators according to RECIST 1.1.
Time Frame: 18 months
|
The percentage of patients who had a tumor response rating of CR, PR, or SD.
|
18 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kangshun Zhu, Dr., Second Affiliated Hospital of Guangzhou Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MIIR-08
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.